Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases.


Journal

Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 24 03 2020
accepted: 31 03 2020
pubmed: 18 9 2020
medline: 7 1 2021
entrez: 17 9 2020
Statut: ppublish

Résumé

RELATIONSHIP BETWEEN MALIGNANCIES AND MUSCULOSKELETAL DISEASES: Oncorheumatology is the meeting point of tumor formation and rheumatic musculoskeletal diseases (RMD). Multiple interactions exist between these two medical specialties. One major field is the topic of malignancies associated with rheumatic diseases, while the other topic covers the development of musculoskeletal disease in cancer patients. Within the first group, secondary malignancies may be associated with rheumatic diseases. Mostly sustained inflammation is responsible for transition into cancer. Tumor-associated antigens (TAA) with adhesive properties are present on tumor cells. These molecules may also be expressed by inflammatory leukocytes and soluble TAA levels may be elevated in RMDs. There has been continuous debate with respect to the possible carcinogenicity of conventional and targeted antirheumatic drugs. Very recent data from registries suggest that neither biologics, nor JAK inhibitors increase cancer risk in arthritis patients. The issue of physiotherapy in rheumatic patients with recent or current cancer has also been controversial. Some modalities, primarily exercise, may be safely applied to patients with RMD and cancer. The second large topic includes paraneoplastic syndromes. Musculoskeletal paraneoplasias are triggered by tumor-derived mediators. These syndromes are sometimes slightly different from the classical RMDs. Various chemotherapies may also be associated with autoimmune side effects. Recently, these immune-related complications have also been observed in cancer patients treated with immune-checkpoint inhibitors. Sex hormone-deprivation therapies, such as aromatase inhibitors and anti-androgens are widely used for the treatment of breast and prostate cancer, respectively. These compounds may induce bone loss and lead to osteoporosis. Finally, primary and secondary malignancies of the musculoskeletal system may also interest rheumatologists. In this review, the clinical, practical aspects of these eight pillars of oncorheumatology will be discussed.

Identifiants

pubmed: 32942035
pii: S1568-9972(20)30233-0
doi: 10.1016/j.autrev.2020.102658
pii:
doi:

Substances chimiques

Antigens, Neoplasm 0
Antirheumatic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102658

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Zoltán Szekanecz (Z)

Division of Rheumatology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Electronic address: szekanecz.zoltan@med.unideb.hu.

Izabella Gomez (I)

Division of Rheumatology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; National Institute of Rheumatology and Physiotherapy, Budapest, Hungary.

Boglárka Soós (B)

Division of Rheumatology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Levente Bodoki (L)

Division of Rheumatology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Szilvia Szamosi (S)

Division of Rheumatology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Csilla András (C)

Department of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Balázs Juhász (B)

Department of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

László Váróczy (L)

Division of Hematology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Péter Antal-Szalmás (P)

Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Péter Szodoray (P)

Division of Clinical Immunology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Institute of Immunology, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Nóra Bittner (N)

Department of Pulmonology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Péter Árkosy (P)

Department of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Árpád Illés (Á)

Division of Hematology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Gabriella Szűcs (G)

Division of Rheumatology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Katalin Dankó (K)

Division of Clinical Immunology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Tamás Bender (T)

Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary.

László Tamási (L)

Department of Rheumatology, Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital, Miskolc;, Hungary.

Éva Szekanecz (É)

Department of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH